Daehan New Pharm Co. Ltd (054670) - Net Assets
Based on the latest financial reports, Daehan New Pharm Co. Ltd (054670) has net assets worth ₩129.44 Billion KRW (≈ $87.72 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩251.53 Billion ≈ $170.46 Million USD) and total liabilities (₩122.10 Billion ≈ $82.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 054670 asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩129.44 Billion |
| % of Total Assets | 51.46% |
| Annual Growth Rate | 5.43% |
| 5-Year Change | 119.56% |
| 10-Year Change | 62.48% |
| Growth Volatility | 22.63 |
Daehan New Pharm Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Daehan New Pharm Co. Ltd's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Daehan New Pharm Co. Ltd to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Daehan New Pharm Co. Ltd (2014–2024)
The table below shows the annual net assets of Daehan New Pharm Co. Ltd from 2014 to 2024. For live valuation and market cap data, see 054670 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩125.44 Billion ≈ $85.01 Million |
+14.71% |
| 2023-12-31 | ₩109.36 Billion ≈ $74.11 Million |
+6.21% |
| 2022-12-31 | ₩102.96 Billion ≈ $69.77 Million |
+24.85% |
| 2021-12-31 | ₩82.47 Billion ≈ $55.89 Million |
+44.34% |
| 2020-12-31 | ₩57.13 Billion ≈ $38.72 Million |
-6.44% |
| 2019-12-31 | ₩61.07 Billion ≈ $41.38 Million |
+41.75% |
| 2018-12-31 | ₩43.08 Billion ≈ $29.19 Million |
-16.71% |
| 2017-12-31 | ₩51.72 Billion ≈ $35.05 Million |
-27.36% |
| 2016-12-31 | ₩71.20 Billion ≈ $48.25 Million |
-7.77% |
| 2015-12-31 | ₩77.20 Billion ≈ $52.32 Million |
+4.49% |
| 2014-12-31 | ₩73.89 Billion ≈ $50.07 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daehan New Pharm Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 596.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩58.89 Billion | 46.94% |
| Common Stock | ₩7.18 Billion | 5.72% |
| Other Components | ₩59.38 Billion | 47.33% |
| Total Equity | ₩125.44 Billion | 100.00% |
Daehan New Pharm Co. Ltd Competitors by Market Cap
The table below lists competitors of Daehan New Pharm Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beyaz Filo Oto Kiralama AS
IS:BEYAZ
|
$53.36 Million |
|
Boom Logistics Ltd
AU:BOL
|
$53.40 Million |
|
Immutep Limited
F:YP1A
|
$53.41 Million |
|
Elicio Therapeutics Inc.
NASDAQ:ELTX
|
$53.44 Million |
|
Chang Type Industrial Co Ltd
TW:1541
|
$53.25 Million |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
$53.24 Million |
|
XTPL SA
WAR:XTP
|
$53.24 Million |
|
Prinsiri Public Company Limited
BK:PRIN
|
$53.24 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daehan New Pharm Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 109,355,896,480 to 125,438,916,500, a change of 16,083,020,020 (14.7%).
- Net income of 15,467,990,700 contributed positively to equity growth.
- Dividend payments of 1,403,528,900 reduced retained earnings.
- Other factors increased equity by 2,018,558,220.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩15.47 Billion | +12.33% |
| Dividends Paid | ₩1.40 Billion | -1.12% |
| Other Changes | ₩2.02 Billion | +1.61% |
| Total Change | ₩- | 14.71% |
Book Value vs Market Value Analysis
This analysis compares Daehan New Pharm Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.63x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.10x to 0.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5073.12 | ₩5600.00 | x |
| 2017-12-31 | ₩3685.05 | ₩5600.00 | x |
| 2018-12-31 | ₩3069.40 | ₩5600.00 | x |
| 2019-12-31 | ₩4350.90 | ₩5600.00 | x |
| 2020-12-31 | ₩4070.60 | ₩5600.00 | x |
| 2021-12-31 | ₩5875.57 | ₩5600.00 | x |
| 2022-12-31 | ₩7335.72 | ₩5600.00 | x |
| 2023-12-31 | ₩7791.50 | ₩5600.00 | x |
| 2024-12-31 | ₩8937.39 | ₩5600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daehan New Pharm Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.33%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.65%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.76x
- Recent ROE (12.33%) is above the historical average (3.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 3.60% | 3.70% | 0.55x | 1.77x | ₩-4.73 Billion |
| 2015 | 5.37% | 4.60% | 0.68x | 1.72x | ₩-3.57 Billion |
| 2016 | -7.97% | -5.18% | 0.84x | 1.84x | ₩-12.79 Billion |
| 2017 | -39.79% | -15.73% | 1.07x | 2.36x | ₩-25.75 Billion |
| 2018 | 5.70% | 2.05% | 1.10x | 2.52x | ₩-1.85 Billion |
| 2019 | 24.96% | 11.36% | 1.05x | 2.09x | ₩9.13 Billion |
| 2020 | -17.38% | -6.64% | 1.12x | 2.33x | ₩-15.64 Billion |
| 2021 | 19.03% | 9.42% | 1.06x | 1.91x | ₩7.45 Billion |
| 2022 | 23.62% | 12.28% | 1.17x | 1.64x | ₩14.02 Billion |
| 2023 | 11.47% | 6.14% | 1.15x | 1.62x | ₩1.61 Billion |
| 2024 | 12.33% | 7.65% | 0.91x | 1.76x | ₩2.92 Billion |
Industry Comparison
This section compares Daehan New Pharm Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $481,699,596,243
- Average return on equity (ROE) among peers: 1.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daehan New Pharm Co. Ltd (054670) | ₩129.44 Billion | 3.60% | 0.94x | $53.26 Million |
| Dongwha Pharm.Co.Ltd (000020) | $378.67 Billion | 5.38% | 0.22x | $87.91 Million |
| Yuhan Corp. (000100) | $1.65 Trillion | 3.48% | 0.32x | $3.67 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 2.42% | 0.28x | $45.29 Million |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $39.15 Million |
| Yuyu Pharma Inc (000225) | $128.69 Billion | -1.72% | 0.50x | $14.81 Million |
| Yuyu Pharma Inc (000227) | $135.06 Billion | 6.46% | 0.54x | $29.39 Million |
| Ildong Holdings Co Ltd (000230) | $105.71 Billion | 13.32% | 1.07x | $46.37 Million |
| Samil Pharm (000520) | $65.75 Billion | -8.13% | 2.44x | $89.20 Million |
| Donga Socio Holdings (000640) | $350.94 Billion | 12.36% | 1.19x | $384.83 Million |
| Jw Pharmac (001060) | $230.09 Billion | -10.98% | 1.49x | $359.11 Million |
About Daehan New Pharm Co. Ltd
Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormo… Read more